Pallisgaard JL, et al. - Authors attempted to determine if insulin-sensitizing therapy (thiazolidinediones and/or metformin) decreased the risk of developing atrial fibrillation compared with insulin-providing therapy (insulin, sulfonylurea, and/or a meglitinide) in patients with type 2 diabetes and documented coronary artery disease. The intention-to-treat analysis disclosed that the incidence of atrial fibrillation was 8.7 per 1,000 person years in patients assigned insulin-sensitization vs 9.5 in patients assigned to insulin-provision. Hence, it was inferred that no prominent reduction of atrial fibrillation incidence was obtained with the use of thiazolidinediones.